Sökning: id:"swepub:oai:gup.ub.gu.se/329927" >
Enasidenib treatmen...
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
-
Geoerger, B. (författare)
-
Schiff, M. (författare)
-
Penard-Lacronique, V. (författare)
-
visa fler...
-
- Darin, Niklas, 1964 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics
-
Saad, S. M. (författare)
-
Duchon, C. (författare)
-
Lamaziere, A. (författare)
-
Desmons, A. (författare)
-
Pontoizeau, C. (författare)
-
Berlanga, P. (författare)
-
Ducassou, S. (författare)
-
Yen, K. (författare)
-
Su, M. (författare)
-
Schenkein, D. (författare)
-
Ottolenghi, C. (författare)
-
De Botton, S. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2023
- 2023
- Engelska.
-
Ingår i: Nature Medicine. - 1078-8956. ; 29:6
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- D-2-hydroxyglutaric aciduria type II (D2HGA2) is a severe inborn disorder of metabolism caused by heterozygous R140 mutations in the IDH2 (isocitrate dehydrogenase 2) gene. Here we report the results of treatment of two children with D2HGA2, one of whom exhibited severe dilated cardiomyopathy, with the selective mutant IDH2 enzyme inhibitor enasidenib. In both children, enasidenib treatment led to normalization of D-2-hydroxyglutarate (D-2-HG) concentrations in body fluids. At doses of 50 mg and 60 mg per day, no side effects were observed, except for asymptomatic hyperbilirubinemia. For the child with cardiomyopathy, chronic D-2-HG inhibition was associated with improved cardiac function, and for both children, therapy was associated with improved daily functioning, global motility and social interactions. Treatment of the child with cardiomyopathy led to therapy-coordinated changes in serum phospholipid levels, which were partly recapitulated in cultured fibroblasts, associated with complex effects on lipid and redox-related gene pathways. These findings indicate that targeted inhibition of a mutant enzyme can partly reverse the pathology of a chronic neurometabolic genetic disorder. In a study of two children with the metabolic condition D-2-hydroxyglutaric aciduria type II, the drug enasidenib, developed as a selective mutant IDH2 inhibitor for treatment of acute myeloid leukemia, had beneficial effects on cardiac and neurodevelopmental abnormalities, indicating the potential for the repurposing of this drug for this hereditary condition.
Ämnesord
- NATURVETENSKAP -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
- NATURAL SCIENCES -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Geoerger, B.
-
Schiff, M.
-
Penard-Lacroniqu ...
-
Darin, Niklas, 1 ...
-
Saad, S. M.
-
Duchon, C.
-
visa fler...
-
Lamaziere, A.
-
Desmons, A.
-
Pontoizeau, C.
-
Berlanga, P.
-
Ducassou, S.
-
Yen, K.
-
Su, M.
-
Schenkein, D.
-
Ottolenghi, C.
-
De Botton, S.
-
visa färre...
- Om ämnet
-
- NATURVETENSKAP
-
NATURVETENSKAP
-
och Biologi
-
och Biokemi och mole ...
- Artiklar i publikationen
-
Nature Medicine
- Av lärosätet
-
Göteborgs universitet